Mirati Therapeutics Receives Positive Opinion From CHMP For Krazati (Adagrasib) As A Targeted Treatment Option For Patients With Advanced Non-small Cell Lung Cancer With A KRASG12C Mutation Following A Re-examination Procedure
Portfolio Pulse from Benzinga Newsdesk
Mirati Therapeutics has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its drug Krazati (Adagrasib) as a targeted treatment for patients with advanced non-small cell lung cancer with a KRASG12C mutation. This follows a re-examination procedure.
November 10, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirati Therapeutics' drug Krazati (Adagrasib) has received a positive opinion from CHMP, potentially opening up a new market for the company.
The positive opinion from CHMP for Krazati (Adagrasib) is a significant regulatory milestone for Mirati Therapeutics. This could potentially lead to the drug's approval in the European market, opening up new market opportunities for the company and potentially driving its stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100